Evidence map›Paper›PMID 42706167›Full record

ReviewZhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi2026

[Mechanism and clinical progress of JAK inhibitors in hemophagocytic lymphohistiocytosis].

M X Wang, Y Z Zhao, Z G Li, T Y Wang, R Zhang

Abstract readReviewEnglish Abstract
PubMed Full text at PMC Publisher
In one paragraph

Review in Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

M X WangDepartment of Hematology, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China.
Y Z ZhaoDepartment of Hematology, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China.
Z G LiHematologic Diseases Research Laboratory, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China.
T Y WangDepartment of Hematology, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China.
R ZhangDepartment of Hematology, Beijing Children's Hospital, Capital Medical University, Beijing 100045, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome characterized by uncontrolled activation of lymphocytes and macrophages. Owing to its marked etiological heterogeneity, HLH is broadly classified into primary and secondary forms. Janus kinase (JAK) inhibitors, represented by ruxolitinib, exert therapeutic effects by blocking the JAK-STAT signaling pathway and suppressing the secretion of various cytokines, including interferon-γ. Accumulating evidence suggests that JAK inhibitors demonstrate unique therapeutic potential across diverse etiological backgrounds of HLH. This review summarizes the mechanisms and clinical research progress of JAK inhibitors in the treatment of HLH.

Indexed as

Janus Kinase InhibitorsLymphohistiocytosis, HemophagocyticHumansJanus KinasesNitrilesPyrazolesPyrimidinesSignal TransductionJanus Kinase InhibitorsJanus KinasesNitrilesPyrazolesPyrimidinesruxolitinib

Identifiers

PMID42706167
PMCPMC13575525

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.